Pavel G Komarov
Overview
Explore the profile of Pavel G Komarov including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
430
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Korotchkina L, Kazyulkin D, Komarov P, Polinsky A, Andrianova E, Joshi S, et al.
Leukemia
. 2020 Jan;
34(7):1828-1839.
PMID: 31896781
Effective treatment of some types of cancer can be achieved by modulating cell lineage-specific rather than tumor-specific targets. We conducted a systematic search for novel agents selectively toxic to cells...
2.
Leonova K, Shneyder J, Antoch M, Toshkov I, Novototskaya L, Komarov P, et al.
Cell Cycle
. 2010 Apr;
9(7):1434-43.
PMID: 20404530
It has been shown that genetic inhibition of p53 leads to enhanced proliferation of hematopoietic stem cells (HSCs). This could, in theory, contribute to the increased frequency of tumor development...
3.
Narizhneva N, Tararova N, Ryabokon P, Shyshynova I, Prokvolit A, Komarov P, et al.
Cell Cycle
. 2009 Dec;
8(24):4155-67.
PMID: 19946220
In prostate cancer (PCa) patients, initial responsiveness to androgen deprivation therapy is frequently followed by relapse due to development of treatment-resistant androgen-independent PCa. This is typically associated with acquisition of...
4.
Burkhart C, Watt F, Murray J, Pajic M, Prokvolit A, Xue C, et al.
Cancer Res
. 2009 Aug;
69(16):6573-80.
PMID: 19654298
The multidrug resistance-associated protein 1 (MRP1) has been closely linked to poor treatment response in several cancers, most notably neuroblastoma. Homozygous deletion of the MRP1 gene in primary murine neuroblastoma...
5.
Strom E, Sathe S, Komarov P, Chernova O, Pavlovska I, Shyshynova I, et al.
Nat Chem Biol
. 2006 Jul;
2(9):474-9.
PMID: 16862141
p53-dependent apoptosis contributes to the side effects of cancer treatment, and genetic or pharmacological inhibition of p53 function can increase normal tissue resistance to genotoxic stress. It has recently been...
6.
Komarova E, Krivokrysenko V, Wang K, Neznanov N, Chernov M, Komarov P, et al.
FASEB J
. 2005 Apr;
19(8):1030-2.
PMID: 15811878
Chronic inflammation is known to promote cancer, suggesting that negative regulation of inflammation is likely to be tumor suppressive. We found that p53 is a general inhibitor of inflammation that...
7.
Komarova E, Neznanov N, Komarov P, Chernov M, Wang K, Gudkov A
J Biol Chem
. 2003 Mar;
278(18):15465-8.
PMID: 12637507
Pifithrin alpha (PFTalpha) is a chemical compound isolated for its ability to suppress p53-mediated transactivation. It can protect cells from p53-mediated apoptosis induced by various stimuli and reduce sensitivity of...